Pharmacogenetics of Drug Metabolism: Overview

Phase I enzymes, primarily cytochrome P450s, catalyze oxidation, reduction, and hydrolysis reactions to chemically modify drugs and xenobiotics. Phase II enzymes then perform conjugation reactions on these modified compounds, further increasing polarity to aid elimination. Together, these enzymatic processes enhance drug clearance from the body.

Genetic polymorphisms create distinct metabolizer phenotypes: ultra-rapid, extensive, intermediate, or poor metabolizers. Each phenotype reflects different enzyme expression or function levels, directly affecting drug metabolism rates. These variations determine therapeutic efficacy and adverse effect risk, making phenotype classification essential for personalized dosing decisions.

CYP2C9 and VKORC1 polymorphisms together explain significant warfarin dose variability. VKORC1 typically accounts for 15–30% of variability, while CYP2C9 contributes 5–10%, depending on population. However, environmental factors like diet and concurrent medications also substantially influence warfarin response, complicating precise clinical dosing.

Multiple overlapping factors influence drug response beyond genetics. Age, weight, diet, and concurrent medications significantly affect drug metabolism and efficacy. While pharmacogenetic profiling predicts individual responses, integrating genotypic data with these environmental variables requires robust clinical validation and standardized guidelines for reliable clinical implementation.

Over seventy FDA-approved drugs currently include pharmacogenetic guidance in their labeling, with some sources indicating over a hundred total. These recommendations inform prescribing decisions and help clinicians optimize drug selection and dosing. However, more robust clinical studies are needed to validate and integrate this data into routine clinical practice.

Phase II enzymes, including acetyltransferase, thiopurine methyltransferase, and UDP glucuronosyltransferase, perform conjugation reactions that further increase drug polarity. These modifications enhance water solubility and facilitate renal or biliary elimination. Genetic variants in Phase II enzymes significantly alter conjugation capacity, affecting individual drug metabolism rates and therapeutic outcomes.

Genetic polymorphisms in drug-metabolizing enzymes directly cause inter-individual variability in drug response by altering enzyme expression or function. These variants can result in ultra-rapid to poor metabolizer phenotypes, each with distinct clinical implications. Pharmacogenetic profiling leverages this knowledge to enable personalized medicine approaches and optimize therapeutic outcomes.